Rose McNulty

The REIMAGINE 1, 2 and 3 trials each met their primary HbA1c end point and confirmatory secondary end points for body weight reduction.

An electronic health record–based model could help health systems target diabetes prevention to the high-risk patients most likely to benefit.

Artificial intelligence models matched mid-career dermatologists but trailed seasoned experts in diagnosing skin lesions across real-world cases.

Survodutide's SYNCHRONIZE trials show weight loss driven by visceral and liver fat, not muscle.

Evolocumab cut major cardiac events by 29% in high-risk diabetes without prior heart attack or stroke in VESALIUS-CV subgroup data from ADA 2026.

A fully remote genetic screening program and a multicenter quality improvement initiative both advanced early type 1 diabetes detection.

Thomas Martens, M.D., explains why CONNECT's 1.6% A1C reduction with continuous glucose monitoring is so exciting in patients with type 2 diabetes not on insulin.

Thomas Martens, M.D., on why outcomes with CGM in CONNECT—including five more hours per day in range—came largely from lifestyle change, not added medication.

Thomas Martens, M.D., explains what drives adoption and how CONNECT's Level A evidence could move CGM coverage.

An electronic health record–based diabetes risk tool helped primary care teams target prevention and reduce progression to type 2 diabetes in prediabetes patients.